Turkish Journal of Medical Sciences
Volume 47

Number 6

Article 7

1-1-2017

Emergency coronary bypass surgery in patients under the
influence of dualantiplatelet therapy: effects of tranexamic acid
and desmopressin acetate
GÖKALP ALTUN
DOĞUŞ HEMŞİNLİ
ZERRİN PULATHAN
ALİ CİVELEK

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
ALTUN, GÖKALP; HEMŞİNLİ, DOĞUŞ; PULATHAN, ZERRİN; and CİVELEK, ALİ (2017) "Emergency coronary
bypass surgery in patients under the influence of dualantiplatelet therapy: effects of tranexamic acid and
desmopressin acetate," Turkish Journal of Medical Sciences: Vol. 47: No. 6, Article 7. https://doi.org/
10.3906/sag-1612-140
Available at: https://journals.tubitak.gov.tr/medical/vol47/iss6/7

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Turkish Journal of Medical Sciences

Turk J Med Sci
(2017) 47: 1708-1714
© TÜBİTAK
doi:10.3906/sag-1612-140

http://journals.tubitak.gov.tr/medical/

Research Article

Emergency coronary bypass surgery in patients under the influence of dual
antiplatelet therapy: effects of tranexamic acid and desmopressin acetate
1,

1

2

1

3

Gökalp ALTUN *, Doğuş HEMŞİNLİ , Zerrin PULATHAN , Ali CİVELEK
Department of Cardiovascular Surgery, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey
2
Department of Cardiovascular Surgery, Kanuni Education and Research Hospital, Trabzon, Turkey
3
Department of Cardiovascular Surgery, Medical Park Hospital, Ordu, Turkey
Received: 29.12.2016

Accepted/Published Online: 23.06.2017

Final Version: 19.12.2017

Background/aim: Bleeding in patients undergoing coronary artery bypass grafting (CABG) while using dual antiplatelet therapy
(DAPT) is a cause of significant morbidity and mortality. The aim of this study is to examine the perioperative hemostatic effects of
tranexamic acid (TnX-A) and desmopressin acetate (Des) in these patients.
Materials and methods: This clinical study was planned in a prospective and randomized manner. Fifty-four patients were enrolled and
classified into 4 different groups. They were compared in terms of various bleeding and transfusion parameters.
Results: No significant differences were observed between the groups in pre/intraoperative data apart from closure times. Plasmin/α-2
antiplasmin complex values in the TnX-A and control groups were significantly higher than those in the Des and TnX-A+Des groups
at the end of postoperative drug infusion. Mean duration of closure times, first 3-h and total postoperative amounts of drainage,
administered volumes of erythrocyte suspension/fresh frozen plasma, cost of blood products, length of intubation, length of stay in the
intensive care unit, and time to discharge were also significantly higher in the Des and control groups.
Conclusion: Des had no significant effect on bleeding control and even delayed the hemostatic efficacy of TnX-A. Use of TnX-A infusion
alone in these patient groups had a positive effect on hemostasis-related data.
Key words: Clopidogrel, coronary bypass surgery, desmopressin acetate, dual antiplatelet therapy, tranexamic acid

1. Introduction
Approximately 10%–20% of allogeneic blood products
worldwide are used in cardiac surgery procedures (1).
Bleeding occurring after cardiac surgery generally
requires large quantities of blood transfusions and
sometimes even reoperation. On the other hand,
excessive blood transfusion is also related to increased
morbidity, mortality, and transmission of viral diseases
(2). According to the statistics, 2% of patients may need
reoperation after coronary artery bypass grafting (CABG).
This complication often results in increased mortality and
prolonged hospitalization (3). Several factors including
prolonged cardiopulmonary bypass (CPB), advanced age,
number of distal anastomoses, hypothermia, insufficient
surgical bleeding control, coagulation disorders, and
platelet dysfunction may result in postoperative bleeding
(4,5). Platelet dysfunction may occur due to both the
effects of CPB on platelet numbers and functions and
the antiplatelet therapy administered in the preoperative
period (3).
* Correspondence: gokalpaltun@gmail.com
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Rates of stent thrombosis, as high as 24% in early
coronary artery stent results, have decreased to 2% with
advances in antiplatelet treatments today (6). Clopidogrel,
a thienopyridine derivative that irreversibly blocks
platelet aggregation, has become the standard treatment
in the prevention of stent thrombosis in interventional
cardiology (7,8). Better results have been observed in both
acute and chronic events with the use of clopidogrel both
alone or in combination with acetylsalicylic acid (ASA) (9).
Studies have shown an increase in the use of clopidogrel
in patients requiring CABG, and an increase in the
incidence of complications associated with postoperative
bleeding has also been noted in these patients (3,7–11).
Postoperative bleeding is still a serious concern for cardiac
surgeons in patients with acute coronary syndrome (ACS)
requiring acute coronary surgery while under the effect of
antiaggregant agents.
In addition to surgical trauma, another important cause
of postoperative bleeding in cardiac surgery is fibrinolysis
triggered by CPB (12). Preoperative antiplatelet therapy
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has also been known as a predisposing factor for excessive
blood loss and need for transfusion in the perioperative
period due to the platelet dysfunction that it causes.
Therefore, there are many pharmacologic agents designed
for ameliorating these adverse effects. For example,
tranexamic acid (TnX-A), a lysine analog, is a synthetic
antifibrinolytic drug. It has positive effect on transfusion
requirements both in cardiac surgeries and reoperations
due to bleeding (12,13). Desmopressin acetate (Des) is
a synthetic arginine vasopressin analog and increases
plasma concentrations of von Willebrand factor (vWF) and
factor VIII (F8), which are involved in platelet adhesion,
by affecting endothelial V2 receptors. Previous clinical
studies have reported that Des can reduce bleeding and
the need for transfusion in patients undergoing cardiac
surgery. It has also been shown to shorten bleeding time in
acquired platelet function disorders such as chronic renal
insufficiency and ASA use (14,15).
The aim of this study was to observe the effects of
TnX-A and/or Des use on clinical and surgical outcomes
as well as on blood product use in patients undergoing
emergency CABG while receiving dual antiplatelet therapy
(DAPT = ASA + clopidogrel).
2. Materials and methods
This clinical study was approved by the Ethics Committee
of the Karadeniz Technical University Faculty of Medicine
and was in accordance with the Declaration of Helsinki.
Informed consent was obtained from every patient in our
study. Initially the study was planned to be a prospective and
randomized study including 80 adult patients undergoing
emergency CABG surgery and receiving DAPT due to
ACS. However, we had to prematurely conclude our study
due to ethical reasons because there were significantly
increased amounts of postoperative drainage in the Des
and control groups compared to the groups receiving
TnX-A. Due to the priority of the patient’s benefit, we
planned to stop the study and consulted with the Ethics
Committee and the Department of Biostatistics. After
consideration, the randomization process was continued
in accordance with the suggestions of biostatisticians who
suggested that stopping the patient enrollment to the Des
and control groups would not affect the power of the study
because there were enough patients in each group. Finally,
the numbers of patients in each group were defined
according to this result.
Our patient group consisted of 54 registered patients
undergoing emergency CABG (47 males, 7 females; mean
age: 63.9 years, range: 46–84). Patients with chronic renal
insufficiency, hepatic dysfunction, hematological disorders,
drug addiction that might affect the hematological system,
requirements for noncoronary cardiac surgery, or use of

intraaortic balloon pumps were excluded from the study.
Preoperative data including concomitant diseases such
as diabetes mellitus (DM), hypertension (HT), chronic
obstructive pulmonary disease (COPD), and carotid artery
stenosis (CAS); demographics such as sex, age, height,
body mass index (BMI), and EuroSCORE values; and
biochemical parameters such as liver and kidney function
tests, blood count, international normalized ratio (INR),
prothrombin time (PT), partial thromboplastin time
(PTT), and bleeding time calculated using the Ivy method
were recorded. All patient groups were operated on by the
same surgical team with standard anesthesia and surgical
techniques. Roller pumps, heparin-uncoated membrane
oxygenators, and cannulas were used in CPB. Number of
distal anastomoses and durations of cross-clamp, CPB, and
closure time (time from heparin neutralization to sternal
closure) were recorded in the operating theater.
Patients were divided into four groups. Patients in the
TnX-A group (n = 18) were started on TnX-A (Transamine,
Fako, 5 mL/250 mg vial) infusions (10 mg/kg of loading
dose in 20 min) at the beginning of the surgical incision,
and then infusion was continued at 1 mg/kg per hour
for 10 h. Patients in the TnX-A+Des group (n = 16) were
administered TnX-A as described. Des (Minirin, Ferring,
4 µg/mL vial) was also administered in 20-min infusions
at a dose of 0.3 µg/kg following neutralization of heparin
with protamine. The Des group (n = 10) only received Des
as described. No drug was administered to the control
group (n = 10).
In the postoperative period, erythrocyte suspension
(ES) was given when hematocrit (Htc) was reduced to
24%, platelet suspension (PLT) was given when platelet
count was decreased below 50 × 103/µL, and fresh frozen
plasma (FFP) was administered to patients with drainage
exceeding 250 mL in the first hour. Postoperatively,
hemoglobin values of patients were recorded initially and
at the 3rd and 24th hours in the ICU. Amounts of drainage
in the first 3 h and total drainage from postoperative
thoracic and mediastinal drains, and the amounts as well
as costs of the blood products used, were recorded. Patients
were closely monitored for development of possible
thrombotic complications (acute myocardial infarction,
cerebrovascular events, and deep vein thrombosis). Length
of intubation and time passed between admission to the
ICU and then discharge were recorded. PAP (Imuclone
PAP ELISA, American Diagnostica Inc.) and vWF
(REAADS, Corgenix Inc.) levels were measured using
commercial ELISA kits from blood taken preoperatively
(T1), after intraoperative heparin neutralization (T2),
at the end of postoperative drug infusion (isotonic fluid
infusion for TnX-A and control groups) (T3), and 1 day
after the end of postoperative drug infusion (T4).
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2.1. Statistical analysis
Numerical data were expressed as mean ± standard
deviation and qualitative data as numbers and percentages
(SPSS 15.0 for Windows 7). The chi-square test was
used for qualitative comparisons, while accordance with
normal distribution of measurement parameters was
assessed using the Kolmogorov–Smirnov test. Measured
data between groups were compared using Kruskal–
Wallis analysis of variance following the establishment of
parametric conditions. The P-value was set at 0.05. The
Mann–Whitney U test was used in post hoc two-way
comparisons by lowering error levels. A new P-value was
calculated by dividing the 0.05 value by the number of twoway comparisons as 0.05 / 3 = 0.016. The Friedman test
was used to assess changes in data in groups over time. The
Wilcoxon test was used in post hoc two-way comparisons
of these data by lowering error levels. The new P-value was
determined as 0.05/6 = 0.008.
3. Results
No significant differences were observed between groups
in terms of demographics, preoperative risk factors, or
preoperative laboratory tests (Table 1). No significant
difference was observed between the TnX-A and TnXA+Des groups in terms of closure times (33.0 min vs.

32.19 min), nor between the Des and control groups (45.0
min vs. 48.0 min). Closure times in the Des and control
groups were significantly longer than those in the TnX-A
and TnX-A+Des groups (P = 0.000) (Table 2). Amounts
of drainage in the first 3 h and in total (Table 3) were not
significantly different, neither between the TnX-A and
TnX-A+Des groups (306 mL, 535 mL vs. 353 mL, 574 mL)
nor between the Des and control groups (785 mL, 1430
mL vs. 972 mL, 1767 mL). Amounts of drainage in the
first 3 h and in total in the Des and control groups were
significantly greater than those in the TnX-A and TnXA+Des groups (P < 0.001).
No significant differences were observed between the
TnX-A and TnX-A+Des groups in terms of amounts of
ES (125 mL vs. 93 mL) and FFP (22 mL vs. 19 mL) used
or blood product costs (66.78 vs. 44.25 Turkish lira, TL).
Similarly, no differences were observed between the Des
and control groups in terms of amounts of ES (675 mL
vs. 900 mL) and FFP used (460 mL vs. 680 mL) or blood
product costs (479.60 vs. 842.80 TL). Levels of ES and FFP
used and blood product costs were significantly higher in
the Des and control groups compared to the TnX-A and
TnX-A+Des groups (P < 0.001). Platelet suspension was
only used in the control group (120 mL) and this was
statistically significant (P = 0.003) (Table 4).

Table 1. Preoperative data (groups n (%) or mean ± standard deviation).
TnX-A
(n = 18)

TnX-A+Des
(n = 16)

Des
(n = 10)

Control
(n = 10)

P-value

Female

3 (16%)

2 (12%)

1 (10%)

1 (10%)

0.94

Age

65.8 ± 6.1

65.6 ± 11.3

66.4 ± 9.3

57.9 ± 14.6

0.45

BMI

28.8 ± 3.6

28.8±5.0

29.3 ± 4.0

28.9 ± 2.9

0.93

Hypertension

11 (61%)

9 (56%)

6 (60%)

6 (60%)

0.99

DM

6 (33%)

5 (31%)

4 (40%)

3 (30%)

0.96

COPD

4 (22%)

6 (37%)

3 (30%)

3 (30%)

0.81

CAS

0 (0%)

1 (6%)

2 (20%)

1 (10%)

0.21

EuroSCORE

3.2 ± 1.5

2.9 ± 1.7

2.5 ± 1.6

2.7 ± 2.0

0.81

Cr (mg/dL)

1.4 ± 1.6

1.0 ± 0.1

0.9 ± 0.2

1.0 ± 0.1

0.41

AST (mg/dL)

27.5 ± 10.4

24.5 ± 11.1

31.6 ± 18.7

27.8 ± 14.2

0.77

ALT (mg/dL)

28.8 ± 13.0

24.6 ± 12.0

26.0 ± 12.9

29.3 ± 8.2

0.72

Hb (g/dL)

14.0 ± 1.8

13.5 ± 1.5

14.3 ± 1.0

13.9 ± 1.4

0.49

Htc (%)

41.1 ± 5.7

40.1 ± 4.2

42.2 ± 2.8

41.4 ± 3.8

0.67

Plt (×103)

222.8 ± 60.6

231.7 ± 99.5

194.7 ± 68.8

230.3 ± 67.7

0.45

PTT (s)

31.3 ± 5.0

30.3 ± 1.7

29.8 ± 2.0

29.9 ± 1.4

0.83

PT (s)

13.2 ± 0.9

13.8 ± 0.7

12.8 ± 1.0

13.2 ± 0.7

0.19

INR

1.1 ± 0.7

1.1 ± 0

1.0 ± 0.1

1.0 ± 0

0.26

Bleeding time

9.9 ± 1.1

9.6 ± 1.2

9.4 ± 1.1

9.4 ± 1.1

0.65

BMI: Body mass index, DM: diabetes mellitus, COPD: chronic obstructive pulmonary disease, CAS: carotid artery stenosis, Cr:
creatinine.
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Table 2. Operative data (groups n (%) or mean ± standard deviation).
TnX-A
(n = 18)

TnX-A+Des
(n = 16)

Des
(n = 10)

Control
(n = 10)

P-value

Use of LIMA

18 (100%)

16 (100%)

10 (100%)

10 (100%)

>0.99

Distal anastomoses

3.3 ± 0.9

3.1 ± 0.7

2.9 ± 0.7

3.0 ± 0.8

Aortic CC time (min)

64.1 ± 12.8

64.6 ± 16.1

62.3 ± 18.0

64.4 ± 16.9

CPB time (min)

121.8 ± 19.4

115.0 ± 23.7

116.5 ± 36.4

116.3 ± 24.9

Closure time (min)

33.0 ± 5.6

32.1 ± 6.3

45.0 ± 4.0

48.0 ± 7.1

0.44
0.98
0.57
0.00

LIMA: Left internal mammary artery, CC: cross-clamp, CPB: cardiopulmonary bypass.
Table 3. Postoperative drainage volume and hemoglobin values.
TnX-A
(n = 18)

TnX-A+Des
(n = 16)

Des
(n = 10)

Control
(n = 10)

First 3 hours of drainage (mL) 306.1 ± 57.1

353.7 ± 39.4

785 ± 129.7

972.5 ± 134.6

Total blood loss (mL)

535 ± 116.8

574.0 ± 75.5

1430 ± 257.6

1767.5 ± 293.2

First Hb (g/dL)

9.1 ± 1.1

9.3 ± 1.4

8 ± 0.3

7.6 ± 0.6

<0.001
<0.001

3rd hour of Hb (g/dL)

10.1 ± 0.7

10.1 ± 1.2

8.7 ± 0.7

8.7 ± 0.4

<0.001

24th hour of Hb (g/dL)

10.8 ± 0.5

10.8 ± 0.8

10 ± 0.5

10.1 ± 0.4

<0.001

P-value
<0.001

Groups n (%) or mean ± standard deviation.
Table 4. The amount of transfused blood products and cost.
TnX-A
(n = 18)

TnX-A+Des
(n = 16)

Des
(n = 10)

Control
(n = 10)

P-value

FFP (mL)

22.2 ± 64.6

0

460 ± 298.8

680 ± 301.1

<0.001

ES (mL)

125 ± 128.6

93.7 ± 125

675 ± 237.1

900 ± 268.7

<0.001

PS (mL)

0

0

0

120 ± 209.7

<0.001

Cost (TL)

66.7 ± 71.9

44.2 ± 59

479.6 ± 204

842.8 ± 536.5

<0.001

Groups n (%) or mean ± standard deviation. ES: Erythrocyte suspension, FFP: fresh frozen plasma, PS: platelet suspension, TL: Turkish
lira.

No significant differences were observed between
the TnX-A and TnX-A+Des groups in terms of length of
intubation (4.24 h vs. 4.08 h), length of stay in the ICU
(41.11 h vs. 42.50 h), and time until discharge (144.1 h vs.
145.3 h). No significant differences were observed between
the Des and control groups in terms of length of intubation
(6.61 h vs. 6.91 h), length of stay in the ICU (64.20 h vs.
75.90 h), or time until discharge (187.30 vs. 189.60 h). All
of these variables were significantly longer in the Des and
control groups compared to the TnX-A and TnX-A+Des
groups (P < 0.001) (Table 5).

No significant difference was observed among the
groups in terms of vWF values (P > 0.05) (Table 6). No
difference was observed between the groups at T1, T2,
or T4 in terms of PAP values (P > 0.05). No significant
difference was observed between the TnX-A and control
groups at T3 (191.50 ng/mL vs. 167.38 ng/mL). Similarly,
there was no significant difference between the TnXA+Des and Des groups (101.69 ng/mL vs. 92.23 ng/mL) at
T3. Measured PAP levels of the TnX-A and control groups
were significantly higher than those of the Des and TnXA+Des groups (P < 0.016) at T3 (Table 7).
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Table 5. Postoperative follow-up periods (groups n (%) or mean ± standard deviation).
TnX-A
(n = 18)

TnX-A+Des
(n = 16)

Des
(n = 10)

Control
(n = 10)

Intubated stay (h)

4.2 ± 0.7

4.0 ± 0.7

6.6 ± 0.5

6.9 ± 0.7

ICU stay (h)

41.1 ± 5.8

42.5 ± 7.1

64.2 ± 22.2

75.9 ± 20.6

Hospital length of stay (h)

144.1 ± 12.1

145.3 ± 9.2

187.3 ± 21.6

189.6 ± 21.6

P-value
<0.001
<0.001
<0.001

ICU: Intensive care unit.
Table 6. vWF values (%) (groups n (%) or mean ± standard deviation).
TnX-A
(n = 18)

TnX-A+Des
(n = 16)

Des
(n = 10)

Control
(n = 10)

P-value

T1

168.8 ± 31.9

190.2 ± 19.6

180.4 ± 47.3

168.8 ± 33.9

0.08

T2

173.3 ± 33.8

188.9 ± 21.9

185.3 ± 36.3

186.3 ± 25.5

0.37

T3

169.5 ± 134.2

185.4 ± 122.3

186.1 ± 124.3

164.8 ± 131.5

0.21

T4

176.3 ± 40

162.9 ± 21.7

168 ± 16.6

157.9 ± 29.4

0.50

vWF: Von Willebrand factor (normal value: 47%–197%), T1: preoperative blood collection time, T2: blood collection time after the
heparin neutralization, T3: blood collection time after the end of postoperative drug infusion (isotonic fluid infusion for TnX-A and
control groups), T4: blood collection time 24 h after the end of drug infusion.
Table 7. PAP values (ng/mL) (groups n (%) or mean ± standard deviation).
TnX-A
(n = 18)

TnX-A+Des
(n = 16)

Des
(n = 10)

Control
(n = 10)

P-value

T1

208.3 ± 87.5

347.9 ± 58.8

233.1 ± 124.1

223.6 ± 22.9

0.53

T2

109.6 ± 44.8

94 ± 48.1

87.5 ± 38.5

114.8 ± 23.4

0.10

T3

191.5 ± 32.6

101.6 ± 40

92.2 ± 50.4

167.3 ± 52.8

0.02

T4

282.2 ± 37.3

204.9 ± 101.9

156.3 ± 96.6

155.2 ± 52.5

0.13

PAP: Plasmin α2 antiplasmin (normal value: 0–514 ng/mL), T1: preoperative blood collection time, T2: blood collection time after the
heparin neutralization, T3: blood collection time after the end of postoperative drug infusion (isotonic fluid infusion for TnX-A and
control groups), T4: blood collection time 24 h after the end of drug infusion.

During the postoperative period, none of our patients
required reoperation due to bleeding or for any other
reason, and neither thrombotic complications nor
mortality occurred.
4. Discussion
The use of DAPT that includes ASA and clopidogrel
is widespread in patients requiring emergency CABG.
Studies have shown that the use of clopidogrel reduces the
risk of cardiovascular events but increases the risk of major
bleeding in patients requiring emergency CABG (6–10).
Increased use of blood products, rate of reoperation due
to bleeding, and duration of hospitalization have also been
reported in these patients (2,3,5–11). Several previous
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studies have reported the effectiveness of hemostatic
agents such as TnX-A and Des on bleeding in elective
coronary surgery (12–15). However, the number of
studies comparing the efficacy of hemostatic agents in
patients undergoing emergency CABG while using DAPT
is limited. Shi et al. compared the effect of TnX-A and a
placebo in patients using DAPT and receiving the final dose
within 7 days before surgery. They reported that TnX-A
significantly reduced blood loss, rate of reoperation, and
amounts of transfusion (16). We observed that bleeding
beginning with skin incision in the form of diffuse tissue
leakage delayed graft preparation and sternal closure in
patients undergoing CABG while receiving DAPT in
our clinic. Delayed sternal closure can result in patient
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cooling, arrhythmias, hemodynamic instability, and an
increased risk of infection. Our results showed that TnX-A
established an approximately 50% decrease in closure time.
In addition, we observed a 3-fold decrease in amounts of
first 3-h and total drainage, and approximately 6- to 9-fold
decreases in amounts of ES used and 19-fold decreases in
blood product costs in the groups administered TnX-A
compared to groups not receiving TnX-A. Similarly,
postoperative Hb levels were higher in the TnX-A groups
in the first hours. TnX-A was also associated with shorter
lengths of intubation, ICU stay, and hospitalization. No
thrombotic complications related to TnX-A were observed
in our patients.
The hemostatic effectiveness of TnX-A in CABG
has been shown in previous studies with patient groups
undergoing elective surgery (13,14). TnX-A has been
reported to reduce blood loss and transfusion requirements
without causing thrombotic complications in patients
receiving ASA until surgery. Our findings are consistent
with the literature and support the idea that TnX-A is
an effective hemostatic agent in patients undergoing
emergency CABG while receiving DAPT therapy.
Fibrinolysis, which is the one of the main reasons for
bleeding in open heart surgery, is triggered by several
factors, and especially by CPB. It lasts for 24 h with
predominance in the first postoperative hours. Therefore,
the idea of initiating antifibrinolytic therapy before CPB
has started to be a point of interest (17,18). Brown et
al. reported 400 mL less drainage in a group started on
TnX-A before CPB than in groups started on it after CPB
in a study involving 91 patients scheduled for elective
CABG (17). Paramo et al. suggested that antifibrinolytics
should be started before CPB (18). Various studies have
been performed with the aim of identifying the correct
dosage of TnX-A. A bolus dose of 10 mg/kg in 20 min
before cutaneous incision followed by infusion at the
rate of 1 mg/kg per hour has been suggested as the ideal
dosage for bleeding control, and increasing the dosage has
been reported as having no additional beneficial effects
on bleeding control (19–21). Similar to our study, the
highest level of postoperative bleeding was observed in
the postoperative first 3 h. We similarly initiated TnX-A
infusion with skin incision at the dosage as described.
Des exhibits its hemostatic effect by increasing plasma
concentrations of vWF and F8, which are responsible for
platelet adhesion. However, Des exhibited no hemostatic
effect in the Des group of our study. In addition, increased
amount of drainage and use of blood products, low
postoperative Hb values, and prolonged intubation, ICU,
and hospitalization times were also observed in this group.
Measured vWF levels supported this idea by showing
no increase in the groups receiving Des. Some previous
studies investigated the hemostatic effects of Des in

patients undergoing CABG. Salzman et al. and Czer et al.
reported that Des reduced blood loss and the need for ES
transfusion by significantly increasing vWF and F8 levels
(22,23). These studies are not consistent with our findings,
mainly because they involved patients who were not under
the effects of antiaggregants in elective conditions.
TnX-A exhibits its antifibrinolytic effects by blocking
plasminogen binding to fibrin. Levels of PAP complex
show that fibrin had formed and the antifibrinolytic
system was activated. In other words, it means that
plasmin was increased. Therefore, it has been used as a
coagulation marker. PAP values at T2 were significantly
lower than values at T1 in all groups. This showed that
anticoagulation was established with heparin. At the same
time, it suggested that coagulation was not sufficient for
fibrin formation at biochemical levels during the process
in which heparin was neutralized by protamine, although
coagulation was started to be observed in the surgical
field. The increase in PAP values over time showed that
the coagulation system gradually recovered after surgery.
Values at T3 significantly increased in the TnX-A and
control groups compared to the groups receiving Des.
However, no significant differences were observed in values
at T3 between the TnX-A and control groups or between
the Des and TnX-A+Des groups. These findings indicate
that Des also suppressed coagulation in the TnX-A+Des
group due to its increasing effect on tissue plasminogen
activator (tPA) and delayed the coagulant effect of TnX-A,
which exhibits its functions by inhibiting plasmin. PAP
values increased significantly at T4 in the groups receiving
TnX-A. PAP values were low at T3 and rapidly increased
at T4 in the TnX-A+Des group. This suggested that the
antifibrinolytic effect of TnX-A was more pronounced
once the effect of tPA had diminished. The significant
increase over time in PAP values in the patients only
receiving TnX-A compared to TnX-A and Des showed
that the present plasmin had been activated. Plasmin was
unable to inhibit the coagulation system since it could not
be used in fibrin breakdown. The significant decrease of
bleeding in the early period in patients receiving TnX-A as
well as the lack of this decrease in the Des and TnX-A+Des
groups support this idea.
In conclusion, on the basis of our findings, Des made
no positive contribution to bleeding control in these
patient groups and delayed the hemostatic effect of TnX-A.
The use of TnX-A infusion alone in these patients had
positive effects on data related to hemostasis. Our findings
support the idea of the routine use of TnX-A in patients
undergoing CABG while using DAPT without significant
adverse effects or heavy financial burden. However, further
controlled randomized and double-blinded studies with
larger patient groups are needed for making definitive
conclusions.
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